Cardiovascular Systems (Nasdaq: CSII ) is expected to report Q2 earnings on Jan. 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cardiovascular Systems's revenues will expand 20.1% and EPS will remain in the red.
The average estimate for revenue is $23.7 million. On the bottom line, the average EPS estimate is -$0.30.
Last quarter, Cardiovascular Systems recorded revenue of $23.3 million. GAAP reported sales were 25% higher than the prior-year quarter's $18.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.26. GAAP EPS were -$0.26 for Q1 versus -$0.22 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 77.4%, 70 basis points better than the prior-year quarter. Operating margin was -22.4%, 580 basis points worse than the prior-year quarter. Net margin was -22.4%, 170 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $96.8 million. The average EPS estimate is -$1.15.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cardiovascular Systems is buy, with an average price target of $13.50.
Is Cardiovascular Systems the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Cardiovascular Systems to My Watchlist.